Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 1.00 |
| ▸ | HTR3A | P46098 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.83 |
| ▸ | REN | P00797 | 6/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Litoxetine SCHEMBL30505553 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Litoxetine SCHEMBL241925 | 0.98 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| SCHEMBL14342835 | 0.91 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Litoxetine SCHEMBL10658633 | 0.88 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Litoxetine SCHEMBL10658612 | 0.88 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| SCHEMBL18616440 | 0.85 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| SCHEMBL8489912 | 0.82 | SLC6A2 (0.84) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Hydrochloric Acid SCHEMBL8493603 | 0.81 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Hydrochloric Acid SCHEMBL8484912 | 0.80 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| SCHEMBL902002 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2270 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-10842772-B1 | Cannabis-based bioactive formulations and methods for use thereof | SEGRETI LOUIS MICHAEL (US) | 2020-11-24 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| CN-104302326-B | Therapeutic use of P75NTR neurotrophin binding proteins | 利维塞普特有限公司 | 2018-03-30 | — | — | CN | claimed |
| US-20170233810-A1 | METHOD AND SYSTEM TO PREDICT SSRI RESPONSE | SHULMAN, VADIM | 2017-08-17 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-9511061-B2 | Incontinence treatment methods | IXALTIS (FR) | 2016-12-06 | — | — | US | claimed |
| CN-105636438-A | Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof | CHEN JIANHONG | 2016-06-01 | — | — | CN | claimed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| EP-0813873-B1 | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | AKZO NOBEL NV (NL) | 2002-02-13 | — | — | EP | claimed |
| US-20020013343-A1 | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors | HEARTDRUG RESEARCH, L.L.C. | 2002-01-31 | — | — | US | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| US-5977099-A | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | AKZO NOBEL, N.V. (NL) | 1999-11-02 | — | — | US | claimed |
| EP-0813873-A1 | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | Akzo Nobel N.V. (NL) | 1997-12-29 | — | — | EP | claimed |
| EP-0264306-B1 | 4-(2-NAPHTHYL METHOXY) PIPERIDINE FOR THE TREATMENT OF OBESITY | SYNTHELABO (FR) | 1991-06-12 | — | — | EP | claimed |
| US-4791119-A | Pharmaceutical composition for treatment of obesity | SYNTHELABO (FR) | 1988-12-13 | — | — | US | claimed |